All News
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative hidradenitis, and Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis, amongst others.
Read Article
No Great Options for Treating VEXAS
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush RheumNow ( View Tweet)
Systemic Score in AOSD to Predict Life-threatening Complications
Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan synovialjoints ( View Tweet)
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
#Behcet’s #syndrome is increasing in the UK
? ⬆️ Detection
? Changing population demographics
? Other reasons
Poster discussion POS0258
#EULAR2024 @RheumNow @eular_org
@Pr1yankaC https://t.co/SEzmJnFMhM
Links:
Janet Pope Janetbirdope ( View Tweet)
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta bella_mehta ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Links:
Bella Mehta bella_mehta ( View Tweet)
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Links:
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Dr. John Cush RheumNow ( View Tweet)
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb
Dr. John Cush RheumNow ( View Tweet)
Cutoffs for sJADAS10
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the sJADAS10, a disease activity measure distinguish patients with ID, MiDA, MoDA, HDA.
https://t.co/A0kIqiOWFE https://t.co/zShqs781W1
Dr. John Cush RheumNow ( View Tweet)
